ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
11.18
-0.14 (-1.24%)
Dec 20, 2024, 4:00 PM EST - Market closed
ARS Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ARS Pharmaceuticals stock have an average target of 24, with a low estimate of 19 and a high estimate of 30. The average target predicts an increase of 114.67% from the current stock price of 11.18.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 8, 2024.
Analyst Ratings
The average analyst rating for SPRY stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +168.34% | Oct 8, 2024 |
| Leerink Partners | Leerink Partners | Buy Maintains $21 → $25 | Buy | Maintains | $21 → $25 | +123.61% | Sep 20, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +168.34% | Sep 16, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +168.34% | Sep 9, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $30 | Buy | Initiates | $30 | +168.34% | Aug 20, 2024 |
Financial Forecast
Revenue This Year
28.69M
from 30.00K
Increased by 95,526.67%
Revenue Next Year
107.86M
from 28.69M
Increased by 275.98%
EPS This Year
-0.50
from -0.57
EPS Next Year
-0.49
from -0.50
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 60.3M | 208.4M | 329.0M | |||
| Avg | 28.7M | 107.9M | 207.9M | |||
| Low | 4.9M | 32.8M | 67.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 200,800.0% | 626.5% | 205.0% | |||
| Avg | 95,526.7% | 276.0% | 92.7% | |||
| Low | 16,233.3% | 14.2% | -37.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.18 | 0.74 | 0.99 | |||
| Avg | -0.50 | -0.49 | -0.11 | |||
| Low | -0.69 | -1.36 | -0.74 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.